Annual EBITDA
-$131.18 M
-$36.81 M-39.01%
30 April 2024
Summary:
KalVista Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$131.18 million, with the most recent change of -$36.81 million (-39.01%) on 30 April 2024. During the last 3 years, it has fallen by -$73.79 million (-128.59%). KALV annual EBITDA is now -7357.48% below its all-time high of -$1.76 million, reached on 31 December 2012.KALV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$43.99 M
-$4.21 M-10.57%
31 July 2024
Summary:
KalVista Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$43.99 million, with the most recent change of -$4.21 million (-10.57%) on 31 July 2024. Over the past year, it has dropped by -$14.44 million (-48.87%). KALV quarterly EBITDA is now -3748.73% below its all-time high of -$1.14 million, reached on 31 December 2013.KALV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$146.27 M
-$15.09 M-11.50%
31 July 2024
Summary:
KalVista Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$146.27 million, with the most recent change of -$15.09 million (-11.50%) on 31 July 2024. Over the past year, it has dropped by -$45.32 million (-44.89%). KALV TTM EBITDA is now -12696.85% below its all-time high of -$1.14 million, reached on 31 December 2013.KALV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.0% | -48.9% | -44.9% |
| 3 y3 years | -128.6% | -87.4% | -99.6% |
| 5 y5 years | -345.5% | -380.1% | -302.9% |
KALV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -128.6% | at low | -287.5% | at low | -99.6% | at low |
| 5 y | 5 years | -345.5% | at low | -398.4% | at low | -302.9% | at low |
| alltime | all time | -7357.5% | at low | -3748.7% | at low | <-9999.0% | at low |
KalVista Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | -$43.99 M(+10.6%) | -$146.27 M(+11.5%) |
| Apr 2024 | -$131.18 M(+39.0%) | -$39.78 M(+20.8%) | -$131.18 M(+22.4%) |
| Jan 2024 | - | -$32.94 M(+11.5%) | -$107.15 M(+6.1%) |
| Oct 2023 | - | -$29.55 M(+2.2%) | -$100.95 M(+4.0%) |
| July 2023 | - | -$28.90 M(+83.4%) | -$97.11 M(+2.9%) |
| Apr 2023 | -$94.37 M(+16.9%) | -$15.76 M(-41.1%) | -$94.37 M(+4.9%) |
| Jan 2023 | - | -$26.75 M(+4.0%) | -$89.97 M(+0.2%) |
| Oct 2022 | - | -$25.71 M(-1.7%) | -$89.75 M(+2.6%) |
| July 2022 | - | -$26.16 M(+130.4%) | -$87.52 M(+8.4%) |
| Apr 2022 | - | -$11.35 M(-57.2%) | -$80.75 M(-7.5%) |
| Apr 2022 | -$80.75 M(+40.7%) | - | - |
| Jan 2022 | - | -$26.53 M(+13.0%) | -$87.30 M(+19.1%) |
| Oct 2021 | - | -$23.48 M(+21.1%) | -$73.28 M(+17.3%) |
| July 2021 | - | -$19.38 M(+8.3%) | -$62.45 M(+8.8%) |
| Apr 2021 | -$57.39 M(+43.4%) | -$17.90 M(+43.0%) | -$57.39 M(+18.8%) |
| Jan 2021 | - | -$12.52 M(-1.0%) | -$48.31 M(-0.1%) |
| Oct 2020 | - | -$12.65 M(-11.6%) | -$48.38 M(+7.8%) |
| July 2020 | - | -$14.31 M(+62.2%) | -$44.89 M(+12.2%) |
| Apr 2020 | -$40.02 M(+35.9%) | -$8.83 M(-29.9%) | -$40.02 M(-5.5%) |
| Jan 2020 | - | -$12.59 M(+37.4%) | -$42.33 M(+16.6%) |
| Oct 2019 | - | -$9.16 M(-3.0%) | -$36.30 M(+13.7%) |
| July 2019 | - | -$9.44 M(-15.2%) | -$31.93 M(+8.4%) |
| Apr 2019 | -$29.44 M | -$11.14 M(+69.9%) | -$29.44 M(+38.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2019 | - | -$6.56 M(+36.9%) | -$21.22 M(+11.9%) |
| Oct 2018 | - | -$4.79 M(-31.2%) | -$18.96 M(-5.5%) |
| July 2018 | - | -$6.96 M(+138.5%) | -$20.06 M(+8.3%) |
| Apr 2018 | -$18.52 M(-16.9%) | -$2.92 M(-32.1%) | -$18.52 M(-10.4%) |
| Jan 2018 | - | -$4.30 M(-27.1%) | -$20.68 M(-15.6%) |
| Oct 2017 | - | -$5.89 M(+8.7%) | -$24.50 M(+16.7%) |
| July 2017 | - | -$5.42 M(+6.8%) | -$21.00 M(-6.8%) |
| Apr 2017 | -$22.30 M(+47.2%) | -$5.08 M(-37.5%) | -$22.52 M(-5.9%) |
| Jan 2017 | - | -$8.12 M(+240.3%) | -$23.93 M(+12.1%) |
| Sept 2016 | - | -$2.38 M(-65.7%) | -$21.35 M(-10.4%) |
| June 2016 | - | -$6.94 M(+7.1%) | -$23.83 M(-7.3%) |
| Apr 2016 | -$15.15 M(-35.6%) | - | - |
| Mar 2016 | - | -$6.49 M(+17.1%) | -$25.69 M(+9.2%) |
| Dec 2015 | -$23.52 M(+192.2%) | -$5.54 M(+13.8%) | -$23.52 M(+6.3%) |
| Sept 2015 | - | -$4.86 M(-44.8%) | -$22.12 M(+5.9%) |
| June 2015 | - | -$8.81 M(+104.1%) | -$20.88 M(+42.9%) |
| Apr 2015 | -$8.05 M(-34.1%) | - | - |
| Mar 2015 | - | -$4.32 M(+4.4%) | -$14.62 M(+19.6%) |
| Dec 2014 | -$12.22 M(+133.0%) | -$4.13 M(+14.2%) | -$12.22 M(+32.4%) |
| Sept 2014 | - | -$3.62 M(+42.4%) | -$9.23 M(+64.5%) |
| June 2014 | - | -$2.54 M(+32.1%) | -$5.61 M(+82.9%) |
| Mar 2014 | - | -$1.93 M(+68.4%) | -$3.07 M(+168.4%) |
| Dec 2013 | -$5.25 M(+198.2%) | -$1.14 M | -$1.14 M |
| Dec 2012 | -$1.76 M | - | - |
FAQ
- What is KalVista Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual EBITDA year-on-year change?
- What is KalVista Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly EBITDA year-on-year change?
- What is KalVista Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals TTM EBITDA year-on-year change?
What is KalVista Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KALV is -$131.18 M
What is the all time high annual EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.76 M
What is KalVista Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, KALV annual earnings before interest, taxes, depreciation & amortization has changed by -$36.81 M (-39.01%)
What is KalVista Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KALV is -$43.99 M
What is the all time high quarterly EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.14 M
What is KalVista Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, KALV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$14.44 M (-48.87%)
What is KalVista Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KALV is -$146.27 M
What is the all time high TTM EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.14 M
What is KalVista Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, KALV TTM earnings before interest, taxes, depreciation & amortization has changed by -$45.32 M (-44.89%)